Case reports suggested that recombinant IL-2 administration could raise CD4+ T cell counts in ICL patients and help improve the clinical outcome of opportunistic infections, including cryptococcal meningitis [6], chronic mycobacterial disease [27], [28], and relapsing herpes zoster infection [29]. The gene discussed is CD4; the disease is Opportunistic infection.